Effects of induction therapy with alemtuzumab versus antithymocyte globulin among highly sensitized kidney transplant candidates
We retrospectively compared induction therapy utilizing alemtuzumab and antithymoglobulin (ATG) in high-risk kidney transplant recipients in our center. Two hundred and fifty-one patients underwent kidney transplantation between 2009 and 2012. The high-risk patients were defined as those who had two...
Gespeichert in:
| Veröffentlicht in: | Saudi journal of kidney diseases and transplantation 2016-07, Vol.27 (4), p.665-670 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 670 |
|---|---|
| container_issue | 4 |
| container_start_page | 665 |
| container_title | Saudi journal of kidney diseases and transplantation |
| container_volume | 27 |
| creator | Geramizadeh, Bita Mutazz al-Din, Nisrin Kazimi, Kourosh Nikeghbalian, Saman Khajerezae, Thurayya Roozbeh, Jamshid Shamsaifar, Ali Rida Malik Husayni, Sayyid Ali |
| description | We retrospectively compared induction therapy utilizing alemtuzumab and
antithymoglobulin (ATG) in high-risk kidney transplant recipients in our center. Two hundred
and fifty-one patients underwent kidney transplantation between 2009 and 2012. The high-risk
patients were defined as those who had two or more times kidney transplantation and/or more
than 30% panel reactive antibody. We studied 130 high-risk kidney transplant candidate; 58
(44.6%) patients received induction immunosuppressive therapy with alemtuzumab, and 72
(55.4%) with ATG. Delayed graft function developed in 11 patients receiving alemtuzumab,
against the 27 patients who receiving ATG (P = 0.021). Acute cellular rejection episodes were
observed in five patients in the alemtuzumab group and 19 patients in the ATG group (P = 0.009).
There were three graft failures in the alemtuzumab group and eight graft failures in the ATG
group due to rejection episodes. We found immunosuppressive induction therapy with
alemtuzumab a significantly less incidence of acute rejection and delayed graft function than
induction therapy with ATG in the high-risk kidney transplant recipients. |
| doi_str_mv | 10.4103/1319-2442.185221 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1805484013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A457649596</galeid><sourcerecordid>A457649596</sourcerecordid><originalsourceid>FETCH-LOGICAL-c520o-44b23f18fa5735e647f95baed7ea9791639771fd919f7f9fe677cd3f45bf133e3</originalsourceid><addsrcrecordid>eNpdks1v1DAQxSMEomXhzgVkCQlxSfFnEh-rqnxIRVzgbDnJeOOuYy-xwyo98afj1W6XlpMP85s34_emKF4TfMEJZh8JI7KknNML0ghKyZPinDKKS9aw5mlxfiqfFS9ivMVYCFlVz4szWnPKq4acF3-ujYEuRRQMsr6fu2SDR2mASW8XtLNpQNrBmOa7edQt-g1TnCPSPuXKMoZuSYDWLrSzsx7pMfg1Gux6cAuK4KNN9g56tLG9hwWlSfu4dbkZddr3ttcJ4svimdEuwqvjuyp-frr-cfWlvPn--evV5U3ZCYpDyXlLmSGN0aJmAipeGylaDX0NWtaSVEzWNTG9JNLkkoGqrrueGS5aQxgDtio-HHS3U_g1Q0xqtLEDl9eBMEdFGix4w3GGV8W7_9DbME8-b5cphgmmXMp_1DobpKw3If-v24uqSy7qistsdqbeP6AG0C4NMbh5b3N8DOID2E0hxgmM2k521NOiCFb7sNU-TbVPUx3Czi1vj3vO7Qj9qeE-3Qx8OwC74FJObuPmHUwqsxsfdo-EywfCqqqEOt6FCkbd30XWe3PQgzwHjD5NrGS2RbC_tN7I3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1830102499</pqid></control><display><type>article</type><title>Effects of induction therapy with alemtuzumab versus antithymocyte globulin among highly sensitized kidney transplant candidates</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Geramizadeh, Bita ; Mutazz al-Din, Nisrin ; Kazimi, Kourosh ; Nikeghbalian, Saman ; Khajerezae, Thurayya ; Roozbeh, Jamshid ; Shamsaifar, Ali Rida ; Malik Husayni, Sayyid Ali</creator><creatorcontrib>Geramizadeh, Bita ; Mutazz al-Din, Nisrin ; Kazimi, Kourosh ; Nikeghbalian, Saman ; Khajerezae, Thurayya ; Roozbeh, Jamshid ; Shamsaifar, Ali Rida ; Malik Husayni, Sayyid Ali</creatorcontrib><description>We retrospectively compared induction therapy utilizing alemtuzumab and
antithymoglobulin (ATG) in high-risk kidney transplant recipients in our center. Two hundred
and fifty-one patients underwent kidney transplantation between 2009 and 2012. The high-risk
patients were defined as those who had two or more times kidney transplantation and/or more
than 30% panel reactive antibody. We studied 130 high-risk kidney transplant candidate; 58
(44.6%) patients received induction immunosuppressive therapy with alemtuzumab, and 72
(55.4%) with ATG. Delayed graft function developed in 11 patients receiving alemtuzumab,
against the 27 patients who receiving ATG (P = 0.021). Acute cellular rejection episodes were
observed in five patients in the alemtuzumab group and 19 patients in the ATG group (P = 0.009).
There were three graft failures in the alemtuzumab group and eight graft failures in the ATG
group due to rejection episodes. We found immunosuppressive induction therapy with
alemtuzumab a significantly less incidence of acute rejection and delayed graft function than
induction therapy with ATG in the high-risk kidney transplant recipients.</description><identifier>ISSN: 1319-2442</identifier><identifier>EISSN: 2320-3838</identifier><identifier>DOI: 10.4103/1319-2442.185221</identifier><identifier>PMID: 27424681</identifier><language>eng</language><publisher>Riyadh, Saudi Arabia: Saudi Center for Organ Transplantation</publisher><subject>Acute renal failure in children ; Alemtuzumab ; Analysis ; Anti-thymocyte globulin ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antilymphocyte Serum ; Antithymocyte globulin ; Care and treatment ; Comparative analysis ; Delayed Graft Function ; Dosage and administration ; Graft Rejection ; Graft Survival ; Health aspects ; Humans ; Immunological aspects ; Immunosuppressive Agents ; Immunotherapy ; Kidney Transplantation ; Kidneys ; Leucopenia ; Organ transplant recipients ; Risk factors ; Transplantation ; Transplantation of organs, tissues, etc. in children ; الأطفال ; الأمراض ; الفشل الكلوي ; الكلى ; علم المداواة ; علم المناعة</subject><ispartof>Saudi journal of kidney diseases and transplantation, 2016-07, Vol.27 (4), p.665-670</ispartof><rights>COPYRIGHT 2016 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt Ltd Jul-Aug 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c520o-44b23f18fa5735e647f95baed7ea9791639771fd919f7f9fe677cd3f45bf133e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27424681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geramizadeh, Bita</creatorcontrib><creatorcontrib>Mutazz al-Din, Nisrin</creatorcontrib><creatorcontrib>Kazimi, Kourosh</creatorcontrib><creatorcontrib>Nikeghbalian, Saman</creatorcontrib><creatorcontrib>Khajerezae, Thurayya</creatorcontrib><creatorcontrib>Roozbeh, Jamshid</creatorcontrib><creatorcontrib>Shamsaifar, Ali Rida</creatorcontrib><creatorcontrib>Malik Husayni, Sayyid Ali</creatorcontrib><title>Effects of induction therapy with alemtuzumab versus antithymocyte globulin among highly sensitized kidney transplant candidates</title><title>Saudi journal of kidney diseases and transplantation</title><addtitle>Saudi J Kidney Dis Transpl</addtitle><description>We retrospectively compared induction therapy utilizing alemtuzumab and
antithymoglobulin (ATG) in high-risk kidney transplant recipients in our center. Two hundred
and fifty-one patients underwent kidney transplantation between 2009 and 2012. The high-risk
patients were defined as those who had two or more times kidney transplantation and/or more
than 30% panel reactive antibody. We studied 130 high-risk kidney transplant candidate; 58
(44.6%) patients received induction immunosuppressive therapy with alemtuzumab, and 72
(55.4%) with ATG. Delayed graft function developed in 11 patients receiving alemtuzumab,
against the 27 patients who receiving ATG (P = 0.021). Acute cellular rejection episodes were
observed in five patients in the alemtuzumab group and 19 patients in the ATG group (P = 0.009).
There were three graft failures in the alemtuzumab group and eight graft failures in the ATG
group due to rejection episodes. We found immunosuppressive induction therapy with
alemtuzumab a significantly less incidence of acute rejection and delayed graft function than
induction therapy with ATG in the high-risk kidney transplant recipients.</description><subject>Acute renal failure in children</subject><subject>Alemtuzumab</subject><subject>Analysis</subject><subject>Anti-thymocyte globulin</subject><subject>Antibodies, Monoclonal</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antilymphocyte Serum</subject><subject>Antithymocyte globulin</subject><subject>Care and treatment</subject><subject>Comparative analysis</subject><subject>Delayed Graft Function</subject><subject>Dosage and administration</subject><subject>Graft Rejection</subject><subject>Graft Survival</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunological aspects</subject><subject>Immunosuppressive Agents</subject><subject>Immunotherapy</subject><subject>Kidney Transplantation</subject><subject>Kidneys</subject><subject>Leucopenia</subject><subject>Organ transplant recipients</subject><subject>Risk factors</subject><subject>Transplantation</subject><subject>Transplantation of organs, tissues, etc. in children</subject><subject>الأطفال</subject><subject>الأمراض</subject><subject>الفشل الكلوي</subject><subject>الكلى</subject><subject>علم المداواة</subject><subject>علم المناعة</subject><issn>1319-2442</issn><issn>2320-3838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdks1v1DAQxSMEomXhzgVkCQlxSfFnEh-rqnxIRVzgbDnJeOOuYy-xwyo98afj1W6XlpMP85s34_emKF4TfMEJZh8JI7KknNML0ghKyZPinDKKS9aw5mlxfiqfFS9ivMVYCFlVz4szWnPKq4acF3-ujYEuRRQMsr6fu2SDR2mASW8XtLNpQNrBmOa7edQt-g1TnCPSPuXKMoZuSYDWLrSzsx7pMfg1Gux6cAuK4KNN9g56tLG9hwWlSfu4dbkZddr3ttcJ4svimdEuwqvjuyp-frr-cfWlvPn--evV5U3ZCYpDyXlLmSGN0aJmAipeGylaDX0NWtaSVEzWNTG9JNLkkoGqrrueGS5aQxgDtio-HHS3U_g1Q0xqtLEDl9eBMEdFGix4w3GGV8W7_9DbME8-b5cphgmmXMp_1DobpKw3If-v24uqSy7qistsdqbeP6AG0C4NMbh5b3N8DOID2E0hxgmM2k521NOiCFb7sNU-TbVPUx3Czi1vj3vO7Qj9qeE-3Qx8OwC74FJObuPmHUwqsxsfdo-EywfCqqqEOt6FCkbd30XWe3PQgzwHjD5NrGS2RbC_tN7I3g</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Geramizadeh, Bita</creator><creator>Mutazz al-Din, Nisrin</creator><creator>Kazimi, Kourosh</creator><creator>Nikeghbalian, Saman</creator><creator>Khajerezae, Thurayya</creator><creator>Roozbeh, Jamshid</creator><creator>Shamsaifar, Ali Rida</creator><creator>Malik Husayni, Sayyid Ali</creator><general>Saudi Center for Organ Transplantation</general><general>Wolters Kluwer - Medknow Publications</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>AACQA</scope><scope>ADJCN</scope><scope>AEION</scope><scope>AHFXO</scope><scope>AHHHR</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160701</creationdate><title>Effects of induction therapy with alemtuzumab versus antithymocyte globulin among highly sensitized kidney transplant candidates</title><author>Geramizadeh, Bita ; Mutazz al-Din, Nisrin ; Kazimi, Kourosh ; Nikeghbalian, Saman ; Khajerezae, Thurayya ; Roozbeh, Jamshid ; Shamsaifar, Ali Rida ; Malik Husayni, Sayyid Ali</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c520o-44b23f18fa5735e647f95baed7ea9791639771fd919f7f9fe677cd3f45bf133e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acute renal failure in children</topic><topic>Alemtuzumab</topic><topic>Analysis</topic><topic>Anti-thymocyte globulin</topic><topic>Antibodies, Monoclonal</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antilymphocyte Serum</topic><topic>Antithymocyte globulin</topic><topic>Care and treatment</topic><topic>Comparative analysis</topic><topic>Delayed Graft Function</topic><topic>Dosage and administration</topic><topic>Graft Rejection</topic><topic>Graft Survival</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunological aspects</topic><topic>Immunosuppressive Agents</topic><topic>Immunotherapy</topic><topic>Kidney Transplantation</topic><topic>Kidneys</topic><topic>Leucopenia</topic><topic>Organ transplant recipients</topic><topic>Risk factors</topic><topic>Transplantation</topic><topic>Transplantation of organs, tissues, etc. in children</topic><topic>الأطفال</topic><topic>الأمراض</topic><topic>الفشل الكلوي</topic><topic>الكلى</topic><topic>علم المداواة</topic><topic>علم المناعة</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geramizadeh, Bita</creatorcontrib><creatorcontrib>Mutazz al-Din, Nisrin</creatorcontrib><creatorcontrib>Kazimi, Kourosh</creatorcontrib><creatorcontrib>Nikeghbalian, Saman</creatorcontrib><creatorcontrib>Khajerezae, Thurayya</creatorcontrib><creatorcontrib>Roozbeh, Jamshid</creatorcontrib><creatorcontrib>Shamsaifar, Ali Rida</creatorcontrib><creatorcontrib>Malik Husayni, Sayyid Ali</creatorcontrib><collection>بنك معلومات "معرفة" لدراسات العلوم العسكرية والأمنية - e-Marefa Military & Security Database</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>مجلس التعاون الخليجي وإيران - e-Marefa The GCC-Iranian Affairs</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>دراسات الشرق الأوسط - e-Marefa Middle Eastern Studies</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Saudi journal of kidney diseases and transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geramizadeh, Bita</au><au>Mutazz al-Din, Nisrin</au><au>Kazimi, Kourosh</au><au>Nikeghbalian, Saman</au><au>Khajerezae, Thurayya</au><au>Roozbeh, Jamshid</au><au>Shamsaifar, Ali Rida</au><au>Malik Husayni, Sayyid Ali</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of induction therapy with alemtuzumab versus antithymocyte globulin among highly sensitized kidney transplant candidates</atitle><jtitle>Saudi journal of kidney diseases and transplantation</jtitle><addtitle>Saudi J Kidney Dis Transpl</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>27</volume><issue>4</issue><spage>665</spage><epage>670</epage><pages>665-670</pages><issn>1319-2442</issn><eissn>2320-3838</eissn><abstract>We retrospectively compared induction therapy utilizing alemtuzumab and
antithymoglobulin (ATG) in high-risk kidney transplant recipients in our center. Two hundred
and fifty-one patients underwent kidney transplantation between 2009 and 2012. The high-risk
patients were defined as those who had two or more times kidney transplantation and/or more
than 30% panel reactive antibody. We studied 130 high-risk kidney transplant candidate; 58
(44.6%) patients received induction immunosuppressive therapy with alemtuzumab, and 72
(55.4%) with ATG. Delayed graft function developed in 11 patients receiving alemtuzumab,
against the 27 patients who receiving ATG (P = 0.021). Acute cellular rejection episodes were
observed in five patients in the alemtuzumab group and 19 patients in the ATG group (P = 0.009).
There were three graft failures in the alemtuzumab group and eight graft failures in the ATG
group due to rejection episodes. We found immunosuppressive induction therapy with
alemtuzumab a significantly less incidence of acute rejection and delayed graft function than
induction therapy with ATG in the high-risk kidney transplant recipients.</abstract><cop>Riyadh, Saudi Arabia</cop><pub>Saudi Center for Organ Transplantation</pub><pmid>27424681</pmid><doi>10.4103/1319-2442.185221</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1319-2442 |
| ispartof | Saudi journal of kidney diseases and transplantation, 2016-07, Vol.27 (4), p.665-670 |
| issn | 1319-2442 2320-3838 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1805484013 |
| source | MEDLINE; Medknow Open Access Medical Journals; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Acute renal failure in children Alemtuzumab Analysis Anti-thymocyte globulin Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antilymphocyte Serum Antithymocyte globulin Care and treatment Comparative analysis Delayed Graft Function Dosage and administration Graft Rejection Graft Survival Health aspects Humans Immunological aspects Immunosuppressive Agents Immunotherapy Kidney Transplantation Kidneys Leucopenia Organ transplant recipients Risk factors Transplantation Transplantation of organs, tissues, etc. in children الأطفال الأمراض الفشل الكلوي الكلى علم المداواة علم المناعة |
| title | Effects of induction therapy with alemtuzumab versus antithymocyte globulin among highly sensitized kidney transplant candidates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T04%3A23%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20induction%20therapy%20with%20alemtuzumab%20versus%20antithymocyte%20globulin%20among%20highly%20sensitized%20kidney%20transplant%20candidates&rft.jtitle=Saudi%20journal%20of%20kidney%20diseases%20and%20transplantation&rft.au=Geramizadeh,%20Bita&rft.date=2016-07-01&rft.volume=27&rft.issue=4&rft.spage=665&rft.epage=670&rft.pages=665-670&rft.issn=1319-2442&rft.eissn=2320-3838&rft_id=info:doi/10.4103/1319-2442.185221&rft_dat=%3Cgale_proqu%3EA457649596%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1830102499&rft_id=info:pmid/27424681&rft_galeid=A457649596&rfr_iscdi=true |